|
Variable
|
No. of studies
|
No. of patients
|
OR (95% CI)
|
P Value
|
I2%
|
|---|
|
Study design
|
|
Retrospective
|
8
|
4212
|
0.71 (0.59–0.84)
|
0.57
|
0
|
|
Prospective
|
2
|
258
|
0.27 (0.09–0.79)
|
0.46
|
0
|
|
Location
|
|
USA
|
5
|
3670
|
0.71 (0.59–0.86)
|
0.52
|
0
|
|
Other
|
5
|
800
|
0.57 (0.36–0.91)
|
0.25
|
25.4
|
|
Study period
|
|
Initiated before 2008
|
4
|
3782
|
0.58 (0.36–0.92)
|
0.15
|
43.4
|
|
Initiated after 2008
|
6
|
688
|
0.71 (0.59–0.85)
|
0.64
|
0
|
|
Mortality recording time
|
|
30-day mortality
|
6
|
3676
|
0.60 (0.48–0.75)
|
0.81
|
0
|
|
90-day mortality
|
7
|
4133
|
0.69 (0.58–0.82)
|
0.30
|
16.9
|
|
Adjustment
|
|
Propensity score matched or multiple adjusted
|
6
|
4040
|
0.69 (0.58–0.83)
|
0.26
|
23.6
|
|
Unadjusted
|
10
|
4779
|
0.74 (0.64–0.87)
|
0.11
|
37.6
|
|
Control group
|
|
NAF or OXA
|
7
|
3910
|
0.69 (0.57–0.83)
|
0.26
|
22.6
|
|
CLX
|
3
|
560
|
0.69 (0.42–1.12)
|
0.46
|
0
|
- ASPs antistaphylococcal penicillins, CFZ cefazolin, CI confidence interval, CLX cloxacillin, MSSA methicillin-susceptible Staphylococcus aureus, NAF nafcillin, OR odds ratio, OXA oxacillin
